Petra Langerbeins - Info zur Person mit Bilder, News & Links

	Cologne

	CLL Paula Cramer Ibrutinib Innere Medizin Anna-Maria Fink Jasmin Klinik Chronic Julia von Tresckow University of Cologne

News

Chronische Lymphatische Leukämie: Gute Optionen auch für komorbide...

www.aerzteblatt.de

Dr. med. Petra Langerbeins. Dr. med. Paula Cramer. Priv.-Doz. Dr. med. Barbara Eichhorst. Prof. Dr. med. Michael Hallek. Klinik I für Innere Medizin und ...

Übersicht aller aktuellen klinisch-onkologischen Studien des CCC ...

cccstudienuebersicht.uk-wuerzburg.de

Deutsche CLL Studiengruppe Klinik I für Innere Medizin Uniklinik Köln Köln. LKP: Uniklinik Köln Dr. Petra Langerbeins Deutsche CLL Studiengruppe

JNCCN CLL - CLL12 Trial: Ibrutinib Improves Outcomes in...

jnccn360.org

... and time to next treatment] in patients with treatment-naive early-stage CLL when compared to placebo,” concluded Petra Langerbeins, MD, ...

Netzwerk-Profile

Jan Durig | AceMap

acemap.openacademic.ai

Petra Langerbeins, Raymonde Busch, Nadine Anheier, Jan Durig, Manuela Bergmann, Mariaelisabeth Goebeler, Hansjurgen Hurtz, Martina Stauch .

Interessen

Lancet Oncology, The - Vol n° 9 - EM consulte

www.em-consulte.com

Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Othman Al-Sawaf, Anja Engelke, Anna-Maria Fink, Kirsten Fischer, ...

Firmen-Mitarbeiter

Über uns | COVIM

covim-netzwerk.de

Dr. Petra Langerbeins. Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, Internistische Intensivmedizin, AP 8 (B-NPL). › ueber-uns

Bücher

Second cancers in chronic lymphocytic leukemia - Taylor ...

www.tandfonline.com

von P Langerbeins · — Petra Langerbeins Department I of Internal Medicine, Center of Integrated Oncology Cologne–Bonn, University Hospital Cologne, Cologne, ... › abs

Dr. Petra Langerbeins - EHA Library

library.ehaweb.org

› eha

Rationelle Diagnostik und Therapie in der Inneren Medizin - Google...

books.google.de

Rationelle Diagnostik und Therapie in der Inneren Medizin

Petra Langerbeins - Eurosurveillance

www.eurosurveillance.org

› ...

Dokumente zum Namen

Chemoimmuntherapien verbessern das Überleben von ...

www.dgim-onlinekongress.de

... Petra Langerbeins. 1, Anna- Maria Fink. 1, Valentin Goede. 1, Thomas Elter. 1, Manuela Bergmann. 4, Martina Stauch. 5, Stephan Stilgenbauer. 4, Clemens-Martin ...

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

Von Tresckow Julia, Paula Cramer, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Petra Langerbeins, Moritz FÃ¼rstenau, Anja Engelke, Anna-Maria Fink, ... › ab...

Poor efficacy and tolerability of R‐CHOP in relapsed/refractory...

www.deepdyve.com

Poor efficacy and tolerability of R-CHOP in relapsed/. refractory chronic lymphocytic leukemia and Richter. transformation. Petra Langerbeins,.

Video & Audio

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage ...

ecancer.org

CLL12 will be presented tomorrow in the late breaking session by Dr Petra Langerbeins who has been the lead in this study for several years ...

How to explain the 'watch-and-wait' period to a CLL patient? |...

www.vjhemonc.com

▶ 1:02Petra Langerbeins, MD of University of Cologne, Cologne, Germany talks about how to explain the 'watch ...

Artikel & Meinungen

Caring for those with haematological disorders during the Covid

www.nature.com

Caring for those with haematological disorders during the Covid-19 pandemic

Sonstiges

(1 - 20 von 45

–alle anzeigen

)

Dr. med. Petra Langerbeins in Köln FA für Innere Medizin

www.aerzte.de

› koeln › nordrhein-westfalen › d...

Petra Langerbeins – iwCLL 2019

iwcll2019.org

› petra-...

Dr Petra LANGERBEINS - Orphanet

www.orpha.net

› cgi-bin › t...

Author Page for Petra Langerbeins :: SSRN

papers.ssrn.com

Total downloads of all papers by Petra Langerbeins

Petra Langerbeins, Ibrutinib versus placebo in patients with ...

www.iwcll.org

› resources

Petra Langerbeins | Lymphoma Hub

lymphomahub.com

Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease

Petra Langerbeins | Videos & Research | VJHemOnc

www.vjhemonc.com

› petra...

Orphanet: Dr Petra LANGERBEINS

www.orpha.net

Das Portal für seltene Krankheiten und Orphan Drugs

DCLLSG | CLL12 Studie

www.dcllsg.de

Eine placebo-kontrollierte, doppelblinde, randomisierte, multizentrische dreiarmige Phase III Studie zu Effektivität und Sicherheit von Ibrutinib vs. Placebo...

DCLLSG | CLL12 Trial

www.dcllsg.de

DCLLSG. Deutsch. CLL12 Trial. Title: A ... Dr. Petra Langerbeins, Internal Medicine I, University Hospital of Cologne : Contact for public queries: Christina Rhein ...

57th ASH Annual Meeting and Exposition (December 5-8, 2015):

ash.confex.com

Julia von Tresckow, MD1*, Paula Cramer, MD2*, Jasmin Bahlo3*, Anja Engelke, MD1*, Petra Langerbeins, MD2*, Anna-Maria Fink, MD2*, Holger Klaproth, ...

Klinische Studien - Onkologie Schwabing - …

www.muenchen-klinik.de

LKP: Dr. Petra Langerbeins. CLL13 (GAIA) Erstlinientherapie fitter Patienten ohne Komorbiditäten. Gegen FCR/BR (Stratifizierung nach Alter) als Standardarm werden drei chemotherapiefreie Arme getestet: Venetoclax plus Rituximab, vs. Venetoclax plus Obinutuzumab vs. Venetoclax plus Obinutuzumab plus Ibrutinib. EudraCT-Nr